Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Family Medicine
Clinical Trials: Solid Tumors
A listing of clinical trials currently looking for volunteers to enroll in Solid Tumors studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : University of Alabama at Birmingham
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Birmingham : Investigational Site Number 840013
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Arizona
Scottsdale : Pinnacle Oncology Hematology,
A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors
Scottsdale : AVEO Clinical Site
A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors
Scottsdale : Mayo Clinic
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Scottsdale : GSK Investigational Site
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
Scottsdale : TGen Clinical Research Services at Scottsdale Healthcare
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
View More »
Scottsdale : GSK Investigational Site
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
Scottsdale : TGEN Clinical Research Services at Scottsdale Healthcare
Dose Escalation Study of NKP-1339 to Treat Advanced Solid Tumors
Scottsdale : Virginia G. Piper Cancer Center at Scottsdale Healthcare
Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors
Scottsdale : TGen Clinical Research Service at Scottsdale Healthcare
Safety Study of PLX108-01 in Patients With Solid Tumors
Scottsdale : TGen Clinical Research Services at Scottsdale Healthcare
Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma
Tucson : GSK Investigational Site
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
Tucson : GSK Investigational Site
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
Tucson : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
California
Duarte : City of Hope
A Maintenance Study Evaluating the Long Term Safety of XL184 in Subjects with Advanced Malignancies Previously Enrolled in Other XL184 Studies
Duarte : City of Hope
A Phase 1, Multi-Center, Open-Label, Dose Escalation Study of I-131-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies
Duarte : City of Hope
A Phase I Trial To Evaluate Safety and Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected with PF-03512676 Adjuvant in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
Duarte : City of Hope
An Open-Label Phase I Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects with Cancer Who Also Have Impaired Renal Function
Duarte : City of Hope
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK 1120212 in Combination with Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, or nab-Paclitaxel in Subjects with Advanced Solid Tumors
Duarte : City of Hope
COG ALTE03N1: Key Adverse Events After Childhood Cancer
Duarte : City of Hope
Evaluation of P53 Specific Immunity
Duarte : City of Hope
Open Label Study of Isavuconazole in the Treatment of Patients with Aspergilloisis and Renal Impairment or of Patients with Invasive Fungal Disease Caused by Rare Molds, Yeasts or Dimorphic Fungi
Duarte : City of Hope
Osteonecrosis of the Jaw (ONC) Case Registry
Duarte : City of Hope
Phase I Trial of Intraperitoneal nab-Paclitaxel (Abraxane) in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity
Duarte : City of Hope
PHI-55 NCI#7427: A Phase I Study of Halichondrin B Analog (E7389) in Combination with Cisplatin in Advanced Solid Tumors
Duarte : City of Hope
PHI-68, NCI #9152: A Phase I Study of ARQ 197 in Combination with IV Topotecan in Advanced Solid Tumors with an Expansion Cohort in Small Cell Lung Cancer
Duarte : City of Hope
PHI-70, NCI #9127: Phase I Trial of Oral 5-Fluoro-2'-Deoxycytidine with Oral Tetrahydrouridine in Patients with Advanced Solid Tumors
Duarte : City of Hope
Sperm Banking Among Adolescents Newly Diagnosed with Cancer: Development of a Profiling and Referral Tool
View More »
Greenbrae : Marin Cancer Care
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
Los Angeles : Samuel Oschin Comprehensive Cancer Institute
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
Los Angeles : UCLA/ University of California Los Angeles Dept. of UCLA (4)
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
Los Angeles : University of Southern California (U.S.C.)/ Norris Comprehensive Cancer Center
Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib
Los Angeles : UCLA
Safety Study of PLX108-01 in Patients With Solid Tumors
Orange : Department of Obstetrics and Gynecology, University of California, Irvine
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Oxnard : PMK Medical Group Inc., DBA Ventura County Hematology Oncology Specialists
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Sacramento : University of California Davis Cancer Center
Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors
Sacramento : University of California at Davis
Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer
San Francisco : Call for Information (Investigational Site 0001)
A Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors (MK-8669-056)
San Francisco : Research Site
Panitumumab Pediatric Study
San Francisco : Call for Information (Investigational Site 0001)
Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)
Santa Maria : Investigational Site Number 840033
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Santa Monica : Call for Information (Investigational Site 0009)
A Dose Escalation Study of MK1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001 AM7)
Santa Monica : UCLA Santa Monica Hematology-Oncology
A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors
Colorado
Aurora : University of Colorado Hospital
A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors
Aurora : Call for Information (Investigational Site 0003)
A Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors (MK-8669-056)
Aurora : Pfizer Investigational Site
A Trial In Patients With Advanced Cancer And Leukemia
Aurora : Children's Hospital Colorado
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors
Aurora : Call for Information (Investigational Site 0003)
Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)
View More »
Denver : Rocky Mountain Cancer Centers - Denver
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Denver : Rocky Mountain Cancer Centers
Safety Study of PLX108-01 in Patients With Solid Tumors
Denver : Investigational Site Number 840008
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Connecticut
New Haven : Research Site
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors
District of Columbia
Washington : GSK Investigational Site
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
Washington : GSK Investigational Site
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
Washington : Research Site
Panitumumab Pediatric Study
Washington : Georgetown Lombardi Comprehensive Cancer Center
Phase I Study of CS-7017 and Bexarotene
Florida
Tampa : H. Lee Moffitt Cancer Center & Research Institute
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Fort Myers : GSK Investigational Site
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
Fort Myers : GSK Investigational Site
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
Jacksonville : Investigational Site Number 840027
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Ocala : Ocala Oncology Center
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Sarasota : Florida Cancer Specialists
Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors
St. Petersburg : Call for Information (Investigational Site 0006)
A Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors (MK-8669-056)
St. Petersburg : All Children's Hospital
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors
St. Petersburg : Call for Information (Investigational Site 0006)
Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)
Tampa : Call for Information (Investigational Site 0004)
Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650 AM1)
Georgia
Savannah : Memorial University Medical Center
ADVL1221: A Phase II Study of Cixutumumab (IMC-A12; IND# 100947) in Combination With Temsirolimus (IND# 61010) in Pediatric Patients With Recurrent or Refractory Solid Tumors
Savannah : Memorial University Medical Center
ANBL00B1: Biomarkers in Tumor Tissue Samples from Patients with Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
View More »
Atlanta : AVEO Clinical Site
A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors
Atlanta : Taofeek Owonikoko, MD, PhD
A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
Atlanta : GSK Investigational Site
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
Atlanta : GSK Investigational Site
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
Illinois
Chicago : Investigational Site Number 840032
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Indiana
Indianapolis : Indiana University Simon Cancer Center IU Simon Cancer Center Clinical Research Office, RT 380
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Lafayette : Horizon Oncology Center
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Lafayette :
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
Iowa
Sioux City : Investigational Site Number 840025
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Louisiana
New Orleans : Ochsner Clinic Foundation
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Maryland
Baltimore : Research Site
A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors
Baltimore : University of Maryland Greenebaum Cancer Center
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Baltimore : Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer
Baltimore : Weinberg Cancer Institution at Franklin Square
Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors
Baltimore : Saint Agnes Healthcare
Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors
View More »
Bethesda : NCI, CCR
Open Label Study to Evaluate the Safety and Tolerability of GI-6301 a Vaccine Consisting of Whole Heat-Killed Recombitant Yeast Genetically Modified to Express Brachyury Protein in Adults With Solid Tumors
Massachusetts
Cambridge : MedComm
Advanced solid tumors including castration-resistant prostate cancer (CRPC)
View More »
Boston : Call for Information (Investigational Site 0003)
A Dose Escalation Study of MK1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001 AM7)
Boston : Dana-Farber / BIDMC / Harvard Cancer Center
A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors
Boston : Dana Farber Cancer Institute SC
A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors
Boston : Dana-Farber Cancer Institute
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Boston : Dana Farber Cancer Institute
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors
Boston : Beth Israel Deaconess Medical Center
Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.
Boston : Dana-Farber Cancer Institute
Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.
Boston : Beth Israel Deaconess Medical Center
Safety Study of PLX108-01 in Patients With Solid Tumors
Boston : Dana Farber Cancer Institute
Safety Study of PLX108-01 in Patients With Solid Tumors
Boston : Massachusetts General Hospital
Safety Study of PLX108-01 in Patients With Solid Tumors
Boston : Call for Information (Investigational Site 0002)
Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650 AM1)
Boston : Beth Israel Deaconess Medical Center (BIDMC) - Cancer Center
Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors
Boston : Massachusetts General Hospital Cancer Center
Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors
Boston : Dana Farber Cancer Institute
Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors
Boston : Investigational Site Number 840030
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Michigan
Ann Arbor : University of Michigan
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Ann Arbor : University of Michigan Comprehensive Cancer Center
A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors
Ann Arbor : University of Michigan Comprehensive Cancer Center
A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors
Ann Arbor : University of Michigan Comprehensive Cancer Center
A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors
Ann Arbor : Research Site
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors
Ann Arbor : University of Michigan Cancer Center
Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas
Detriot : Karmanos Cancer Institute
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
Detroit : GSK Investigational Site
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
Detroit : Wayne State University Department of Oncology Karmanos Cancer Institute
A Study of DS-2248, in Subjects With Advanced Solid Tumors
Detroit : ImClone Investigational Site
A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors
Detroit : ImClone Investigational Site
A Study to Assess the Pharmacokinetics of Ramucirumab in Combination With FOLFIRI
Detroit : Pfizer Investigational Site
A Trial In Patients With Advanced Cancer And Leukemia
Detroit : GSK Investigational Site
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
Detroit : Karmanos Cancer Institute
Safety Study of AB0024 in Patients With Advanced Solid Tumors
Detroit : Wayne State University/Karmanos Cancer Institute
Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors
Detroit : Investigational Site Number 840001
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Minnesota
Minneapolis : Minnesota Oncology Hematology P.A.
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Minneapolis : Research Site
Panitumumab Pediatric Study
Minneapolis : Investigational Site Number 840006
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Rochester : Mayo Clinic
Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas
Mississippi
Jackson : Investigational Site Number 840002
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Missouri
Kansas City : Children's Mercy Hospital & Clinics
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors
St. Louis : Investigational Site Number 840004
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Nevada
Las Vegas : ImClone Investigational Site
A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors
Las Vegas : ImClone Investigational Site
A Study to Assess the Pharmacokinetics of Ramucirumab in Combination With FOLFIRI
Las Vegas : Comprehensive Cancer Centers of Nevada
Safety Study of PLX108-01 in Patients With Solid Tumors
Las Vegas : Investigational Site Number 840022
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
New Hampshire
Lebanon : GSK Investigational Site
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
Lebanon : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
New Jersey
Hackensack : Hackensack University Medical Center
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Morristown : Morristown Memorial Hospital
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Voorhees : Investigational Site Number 840017
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
New Mexico
Albuquerque : Research Site
A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors
New York
Bronx : Einstein-Montefiore Institute for Clinical & Translational Research
A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy
Bronx : Einstein-Montefiore Institute for Clinical & Translational Research
Phase 1/2 Study of PX-866 and Docetaxel in Patients with Solid Tumors
Bronx : Einstein-Montefiore Institute for Clinical & Translational Research
Phase I Safety Study of Clostridium Novyi-NT Spores in Patients with Treatment-Refractory Solid Tumor Malignancies
Bronx : Biomedical Research Alliance of New York
Solid Tumors - Adults
View More »
Albany : New York Oncology Hematology, P.C.
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Albany : Investigational Site Number 840010
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Buffalo :
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
Great Neck : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
New York : Memorial Sloan Kettering Cancer Center
BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
New York : Memorial Sloan-Kettering Cancer Center
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors
New York : Memorial Sloan Kettering Cancer Center
Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors
New York : Research Site
Panitumumab Pediatric Study
New York : Mount Sinai Medical Center
Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors
New York : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
New York : Memorial Sloan-Kettering Cancer Center (MSKCC)
Safety Study of PLX108-01 in Patients With Solid Tumors
New York : Memorial Sloan-Kettering Cancer Center
Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors
New York city : Department of Radiation oncology, Memorial Sloan Kettering Cancer Center
Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.
North Carolina
Durham : Duke University
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Chapel Hill : UNC/Lineberg Comprehensive Cancer Center Lineberger Comp Cancer Ctr
A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors
Charlotte : Blumenthal Cancer Center - Main
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Charlotte : Investigational Site Number 840015
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Durham : Duke University Medical Center
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Durham : GSK Investigational Site
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
Durham : Duke Cancer Institute
Dose Escalation Study of Pazopanib Plus TH-302
Durham : Duke University Medical Center
Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas
Durham : Duke University Medical Center DUMC
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
Durham : Duke University Medical Center
Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors
Huntersville : ImClone Investigational Site
A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors
Ohio
Cincinnati : Cincinnati Children's Hospital Medical Center/Cincinnati Children's Research Foundation
ADVL0612: A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children with Refractory Solid Tumors
Cincinnati : Cincinnati Children's Hospital Medical Center/Cincinnati Children's Research Foundation
ADVL0815: A Phase I Study of Pazopanib as a Single Agent for Children with Refractory Solid Tumors
Cincinnati : Cincinnati Children's Hospital Medical Center/Cincinnati Children's Research Foundation
ADVL0816: A Phase I Study of Obatoclax (Pan Anti-Apoptotic BCL-2 Family Small Molecule Inhibitor), in Combination with Vincristine/Doxorubicin/Dexrazoxane, in Children with Relapsed/Refractory Solid Tumors or Leukemia
Cincinnati : Cincinnati Children's Hospital Medical Center/Cincinnati Children's Research Foundation
Phase I Study of the RAF Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children with Refractory Solid Tumors or Refractory Leukemias
Cincinnati : Cincinnati Children's Hospital Medical Center/Cincinnati Children's Research Foundation
VITAC: A Pilot Study of the Addition of Bevacizumab to Vincristine, Oral Irinotecan and Temozolomide (VOIT regiment) for Relapsed/Refractory Pediatric Solid Tumors
View More »
Cincinnati :
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
Cleveland : ImClone Investigational Site
A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors
Cleveland : University Hospitals Case Medical Center
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Columbus : The Ohio State University - Comprehensive Cancer Center
Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma
Middletown : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Oklahoma
Oklahoma City : University of Oklahoma Health Sciences Center
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Oklahoma City : University of Oklahoma
Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors
Oregon
Eugene : Willamette Valley Cancer and Research / USOR
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Portland : Research Site
Panitumumab Pediatric Study
Portland : Oregon Health and Sciences University
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma Multiforme or Other Recurrent Malignant Gliomas
Portland : Providence Cancer Center
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma Multiforme or Other Recurrent Malignant Gliomas
Tualatin : Northwest Cancer Specialists, P.C.
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Pennsylvania
Philadelphia : ImClone Investigational Site
A Study to Assess the Pharmacokinetics of Ramucirumab in Combination With FOLFIRI
Philadelphia :
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
Philadelphia : University of Pennsylvania
Safety Study of PLX108-01 in Patients With Solid Tumors
Philadelphia : Fox Chase Cancer Center
Safety Study of PLX108-01 in Patients With Solid Tumors
Philadelphia : Pennsylvania Oncology Hematology Associates
Safety Study of PLX108-01 in Patients With Solid Tumors
View More »
Philadelphia : Pennsylvania Oncology
Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors
Pittsburgh : ImClone Investigational Site
A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors
Pittsburgh : UPMC Shadyside Radiation Oncology
Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.
South Carolina
Greenville : Saint Francis Hospital
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Tennessee
Nashville : Sarah Cannon Research Institute
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Memphis : GSK Investigational Site
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
Memphis : Call for Information (Investigational Site 0005)
A Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors (MK-8669-056)
Memphis : GSK Investigational Site
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
Memphis : Call for Information (Investigational Site 0005)
Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)
Memphis : Investigational Site Number 840028
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Nashville : GSK Investigational Site
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
Nashville : Sarah Cannon Research Institute DeptofSarahCannonRes.Inst. (2)
A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors
Nashville : GSK Investigational Site
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
Nashville : The Sarah Cannon Research Institute
Dose Escalation Study of NKP-1339 to Treat Advanced Solid Tumors
Nashville : Tennessee Oncology, PLLC
Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors
Nashville : Vanderbilt-Ingram Medical Center
Safety Study of PLX108-01 in Patients With Solid Tumors
Nashville : Sarah Cannon Research Institute Tennessee Oncology Drug Development Unit
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Texas
Austin : Investigational Site Number 840007
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Dallas : Texas Oncology - Medical City Dallas
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Dallas : Texas Oncology - Dallas Presbyterian
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Dallas : UT Southwestern Medical Center - Simmons Cancer Center
Clinical Trial of ARQ 761 in Advanced Solid Tumors
Dallas : Mary Crowley Cancer Research Center
Phase 1 Study of ONT-10 in Patients With Solid Tumors
View More »
Dallas : Mary Crowley Cancer Research Centers
Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer
Dallas : Texas Oncology, PA (North)
Safety Study of PLX108-01 in Patients With Solid Tumors
Dallas : Mary Crowley Cancer Research Centers
Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
El Paso : Investigational Site Number 840003
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Fort Worth : Texas Oncology - Fort Worth 12th Avenue
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Houston : Research Site
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors
Houston : The University of Texas M. D. Anderson Cancer Center
A Study of QBI-139 in Subjects With Advanced Solid Tumors
Houston : MD Anderson Cancer Center / University of Texas
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Houston : Research Site
Panitumumab Pediatric Study
Houston : UT MD Anderson Cancer Center
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
Houston : UT MD Anderson Cancer Center
Phase 1 Study of BAX69 in Solid Tumors
Houston : MD Anderson Cancer Center
Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer
Houston : Call for Information (Investigational Site 0003)
Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650 AM1)
Plano : Investigational Site Number 840019
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Round Rock : Texas Oncology - Central Austin Cancer Center
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
San Antonio : South Texas Accelerated Research Therapeutics
A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors
San Antonio : South Texas Accelerated Research Therapeutics
A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors
San Antonio :
A First in Man Trial for Patients With Cancer
San Antonio : AVEO Clinical Site
A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors
San Antonio : South Texas Accelerated Research Therapeutics, LLC
A Study of DS-2248, in Subjects With Advanced Solid Tumors
San Antonio : START - South Texas Accelerated Research Therapeutics, LLC
Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects
San Antonio : START - South Texas Accelerated Research Therapeutics, LLC
Effect of Tivantinib on the QTC Interval in Cancer Subjects
San Antonio : South Texas Accelerated Research Therapeutics, LLC
Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors
San Antonio : Cancer Therapy & Research Center / UT Health Science Center SC
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
San Antonio : South Texas Accelerated Research Therapeutics (START)
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
San Antonio :
REGN910 (SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies
San Antonio : South Texas Accelerated Research Therapeutics
Safety Study of AB0024 in Patients With Advanced Solid Tumors
San Antonio : South Texas Accelerated Research Therapeutics, LLC (START)
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
San Antonio : START- South Texas Accelerated Research Therapeutics, LLC
Study of PM060184 in Patients With Advanced Solid Tumors
San Antonio :
Study of REGN910 (SAR307746)
Utah
Salt Lake City : ImClone Investigational Site
A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors
Salt Lake City : GSK Investigational Site
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
Virginia
Christianburg : Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Fairfax : Virginia Cancer Specialists, PC
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Norfolk : Virginia Oncology Associates
Safety Study of PLX108-01 in Patients With Solid Tumors
Norfolk : Investigational Site Number 840005
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Washington
Seattle : University of Washington- Seattle Cancer Care Alliance
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Edmonds : Puget Sound Cancer Centers
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Seattle : Research Site
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors
Spokane : Evergreen Hematology & Oncology
Safety Study of PLX108-01 in Patients With Solid Tumors
Spokane Valley : Cancer Care Northwest
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Vancouver : Investigational Site Number 840009
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Yakima : Yakima Valley Memorial Hospital / North Star Lodge
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Wisconsin
Madison : University of Wisconsin Comprehensive Cancer Center
A Study of QBI-139 in Subjects With Advanced Solid Tumors
Madison : Kenneth DeSantes., MD
Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors
Australia
Bentleigh East : Research Site
A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors
Bunbury : St. John of God Hospital, Bunbury
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Frankston : Frankston Hospital
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Kurralta Park : Research Site
A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors
Launceston : Launceston Gerenal Hospital
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
View More »
North Terrace : Royal Adelaide Hospital
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Parkville : Research Site
A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors
Perth : Sir Charles Gairdner Hospital
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Randwick : Research Site
Phase I Comparative Bioavailability Study
South Brisbane : Mater Adult Hospital
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Subiaco : St. John of Gog Hospital, Subiaco
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
WestMead : WestMead Hospital
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Wodonga : Border Medical Oncology
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Austria
Graz : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Graz : Glycotope Investigational Site
TrasGEX™: Dose Escalation Study
Innsbruck : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Innsbruck : Glycotope Investigational Site
TrasGEX™: Dose Escalation Study
St Poelten : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
View More »
Wels : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Wien : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Belgium
Aalst : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bonheiden : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brasschaat : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brugge : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brussels : Institut Jules Bordet
A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid Tumors
View More »
Eupen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Gent : Novartis Investigative Site
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
Gilly : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Leuven : Research Site
Phase I Comparative Bioavailability Study
Leuven : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Leuven : Investigational Site Number 056002
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Liege : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Mechelen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Namur : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Oostende : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Sint-Niklaas : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Verviers : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Wilrijk : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Canada
Toronto, Ontario : Princess Margaret Hospital
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Kirkland : Merck Frosst Canada Ltd.
A Dose Escalation Study of MK1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001 AM7)
Montreal : McGill University
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Toronto : Princess Margaret Hospital
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Toronto :
REGN910 (SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies
Toronto :
Study of REGN910 (SAR307746)
Vancouver : Novartis Investigative Site
A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors
Czech Republic
Kralove : University Hospital Hradec Kralove
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Ostrava- Poruba : University Hospital Ostrava
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Prague : General University Hospital, Department of Obstetrics and Gynecology
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
France
Aix en Provence : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Aix en Provence cedex 01 : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Amiens : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bayonne : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Besançon Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
View More »
Bordeaux : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bordeaux : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Bourg en Bresse : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brive la Gaillarde : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Caen Cedex 05 : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Clichy : Hopital Beaujon - AP-HP
A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid Tumors
Colmar Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Courbevoie : Laboratoires Merck Sharp & Dohme - Chibret
A Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors (MK-8669-056)
Courbevoie : Laboratoires Merck Sharp & Dohme - Chibret
Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)
Dijon : Investigational Site Number 250002
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Dijon cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
La Roche Sur Yon Cedex 9 : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
La Seyne Sur Mer : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Le Mans Cedex 9 : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Longjumeau cedex 1 : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Marseille : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Marseille : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Mont de Marsan : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Nancy : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Nantes Cedex 2 : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Orléans : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Périgueux cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Paris Cedex 20 : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Pierre Bénite Cedex : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Pontoise Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Pringy Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Reims : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Reims Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Rouen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Saint Grégoire cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Saint Quentin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Soissons Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Soyaux : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Strasbourg : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Toulouse : Institut Claudius Regaud
A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid Tumors
Toulouse : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Vichy cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Villefranche Sur Saone Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Villejuif : Institute Gustave Roussy
Study of Oral E-3810, a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors
Germany
Augsburg : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Berlin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Berlin : MediOnko-Institut GRR
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Berlin : Onkoplan GmbH/ Onkologische Schwerpunktpraxis
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Berlin : "Medizinisches Versorgungszentrum
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
View More »
Berlin : Fachärzte für Innere Medizin - Hämatologie u. Internistische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Bonn : "Praxiskooperation Bonn-Euskirchen
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Borken : "Facharzt für Innere Medizin
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Brandenburg : Frauenarzt
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Bremerhaven : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Chemnitz : Poliklinik GmbH Chemnitz
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Cottbus : Fachärztin für Innere Medizin / Hämatologie / Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Dresden : "Facharzt für Innere Medizin/
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Eisenach : "Facharzt für Innere Medizin Hamatologie und Internistische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Frankenthal : Internist / Hämatologe / Intern. Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Frankfurt : Novartis Investigative Site
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
Freiburg : University Hospital Freiburg Gynecological Clinic
Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer
Garbsen : Internist - Hämatologe - Onkologe
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Gosiar : Hämatologie und Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Goslar : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Groitzsch : Medizinisches Studien- und Dokumentationszentrum
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Halberstadt : FA für Innere Medizin - Hämatologie - Internistische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Halle/Saale : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Hamburg : Novartis Investigative Site
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
Hamburg : University Hospital Hamburg-Eppendorf
Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer
Hannover : MediProjekt Ges. f. Medizinstatistik und Projektentwicklung
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Hannover : Internist - Hämatologe - Onkologe
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Hannover : Novartis Investigative Site
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
Heidenheim : ODZ-Petersen GmbH
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Herne : DOKUSAN Gesellschaft für medizinische Studien mbH & Co. KG
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Jena : "Medizinisches Versorgungszentrum MP Saaletal GmbH
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Köln : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Kassel : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Kassel : Hospital Kassel
Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer
Krefeld : OnkoMed GbR
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Mannheim : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Munchen : Facharzte fur Innere Medizin - Hamatologie u. Intermistische Onkologie - Bluttransfusionswesen
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Munchen : Facharzle fur Innere Medizin - Hamatologie u. Intemistische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Munster : Gemeinschaftspraxis für Hämatologie und Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Neunkirchen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Neuss : Tumorzentrum Niederrhein GmbH
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Oberhausen : Überörtliche Gemeinschaftspraxis
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Oberhausen : Facharzt für Frauenheilkunde und Geburtshilfe
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Olpe : Medizinisches Versorgungszentrum Onkologische Schwerpunktpraxis
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Oranienburg : Fachärztin für Frauenheilkunde und Geburtshilfe
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Osnabruck : Paracelsusklinik
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Paradiese : Medizinisches Versorgungszentrum GbR
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Parchim : FA f. Innere Medizin, Onkologie und Endokrinologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Parchim : Frauenarzt
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Plauen : FA für Innere Medizin
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Remscheid : Facharzt für Innere Medizin - Medikamentöse Tumortheraphie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Rodgau : Frauenarzt
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Rotenburg (Wümme) : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Schoenebeck : FA fur Innere Medizin - Hamatologie - Intermistische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Soest : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Stralsund : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Stralsund : "FA f. Frauenheilkunde und Geburtshilfe SP Gynakologische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Velbert : Praxis fur Hamatologie und Internistische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Verden : Facharzt für Innere Medizin Hamatologie und Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
VS-Villingen : Onkologische Schwerpunktpraxis Hamatologie und Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Würselen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Würzburg : University Hospital Würzburg
Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer
Hong Kong
Shatin, New Territories : Novartis Investigative Site
Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
Israel
Petach Tikva : Rabin Medical Center
Evaluation of [18F]-ML-10 as a PET Imaging Radiotracer for Early Detection of Response of Brain Metastases to Whole Brain Radiation Therapy
Italy
Cefalù PA : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Milan : Instituto Europeo di Oncologia
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Milano : Pfizer Investigational Site
Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials
Milano : Novartis Investigative Site
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
Milano : European Institute of Oncology
Study of Oral E-3810, a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors
View More »
Modena : Novartis Investigative Site
A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors
Napoli : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Padova : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Roma : Oncology IDI- IRCSS
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Roma : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Rozzano : Novartis Investigative Site
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
Torino : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Verona : Novartis Investigative Site
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
Japan
Korea, Republic of
Seoul : Novartis Investigative Site
Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
Netherlands
Amstelveen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Amsterdam : Nationaal Kanker Instituut (NKI)
GLPG0187: Safety, Tolerability and Pharmacokinetics in Patients With Solid Tumors
Amsterdam : Novartis Investigative Site
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
Dordrecht : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Enschede : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
View More »
Haarlem : Merck Sharp & Dohme B.V.
A Dose Escalation Study of MK1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001 AM7)
Leiderdorp : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Maastricht : Novartis Investigative Site
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
Purmerend : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Roosendaal : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Utrecht : Universitair Medisch Centrum
GLPG0187: Safety, Tolerability and Pharmacokinetics in Patients With Solid Tumors
Vlissingen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Zutphen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Poland
Bialystok : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Gdansk : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Koszalin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Krakow : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Lubin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
View More »
Lublin : III Oddzial Onkologii Ginekologicznej
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Olsztyn : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Poznan : Klinika Onkologii AM w Poznaniu
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Poznan : Oddzial Radioterapii
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Poznan : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Walbrzych : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Warszawa : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Wroclaw : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Romania
Alba Iulia : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Baia-Mare : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brasov : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bucharest : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bucuresti : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
View More »
Cluj Napoca : Institutul Oncologic Prof. Dr. Ion. Chiricuta Sectia Radiologie
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Cluj Napoca : Institutul Oncologic Prof. Dr. Ion. Chiricuta Sectia de Oncologie Medicala
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Cluj-Napoca : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Iasi : Oncology Medical Centre SCM
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Mures : Clinical Caunty Hospital Mures
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Oradea : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Ramnicu Valcea : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Targu Mures : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Timisoara : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Russian Federation
Moscow : Moscow City Oncology Hospital
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Moscow : Central Clinical Hospital
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Obninsk : State Institution Medical Radiology Scientific Center
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
St. Petersburg : Sity Clinical Oncology
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Singapore
Singapore : Novartis Investigative Site
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
Spain
Barcelona : Novartis Investigative Site
A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors
Valencia : Investigational Site Number 724001
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Switzerland
Bellinzona : Ospedale San Giovanni
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Bellinzona : Research Site
Phase I Comparative Bioavailability Study
Taiwan
Tainan : National Cheng Kung University Hospital
A Dose Escalation Study of SCB01A in Subjects With Advanced Solid Tumors Who Have Failed Standard Therapy
Tainan 704 : Novartis Investigative Site
Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
Taipei : Novartis Investigative Site
Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
United Kingdom
Edinburgh : Research Site
Phase I Comparative Bioavailability Study
Hoddesdon : Merck Sharp & Dohme Ltd.
A Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors (MK-8669-056)
Hoddesdon : Merck Sharp & Dohme Ltd.
Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)
Hoddesdon : Merck Sharp & Dohme Ltd.
Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650 AM1)
London : Royal Marsden Hospital
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
View More »
London : University College Hospital
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Manchester : The Christie NHS Foundation Trust
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Manchester : Research Site
Phase I Comparative Bioavailability Study
Newcastle : Research Facility
Phase I Comparative Bioavailability Study
Northwood : Mount Vernon Cancer Center
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Northwood : Research Site
Phase I Comparative Bioavailability Study
Oxford : Churchill Hospital
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Oxford : Research Site
Phase I Comparative Bioavailability Study
Sutton : Drug Development Unit Royal Mardsen NHS Foundation Trust
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Sutton : Research Site
Phase I Comparative Bioavailability Study
Sutton : Royal Marsden Hospital
Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma
Withington : Christie NHS Foundation Trust
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
